▮ Content Licensing

▮ Premium NEW

▮ More

Wall Street Events

DXC Technology To Participate In Cowen Technology Conference At 9:40 AM ET

By RTTNews Staff Writer ✉ | Published: 6/2/2022 8:40 AM ET

DXC Technology Company (DXC) will participate in the Cowen Technology Conference.

The event is scheduled to begin at 9:40 AM ET on June 2, 2022.

To access the live webcast, log on to https://investors.dxc.com/events-and-presentations/default.aspx

For comments and feedback contact: editorial@rttnews.com

Business News

Biotech Stocks Facing FDA Decision In September

Biotech Stocks Facing FDA Decision In June 2022

Biotech Stocks Facing FDA Decision In March 2022

Latest Updates on COVID-19

Covid Conditions Improving Nationally In US, Data Shows

U.S. Covid Cases Fall 29% In Last Fortnight

Pfizer, BioNTech Apply For EUA In US Of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster In Kids

Synairgen Reports Positive 60 And 90-day Long COVID Data From Phase 3 SNG001 Trial; Stock Up

AstraZeneca's Evusheld Gets CHMP Recommendation For EU Approval To Treat COVID-19

COVID-19: Drugs in Development

Macy's To Hire More Than 41,000 Seasonal Colleagues

Ladders Sold With Bunk Bed And Hutch Sets Recalled

Lyft To Offer Rides For Indeed's Ready To Work Program

Pool And Spa Drain Covers Sold At Amazon Recalled

Target Unveils Holiday Offers; To Hire Up To 100K Seasonal Staff

DXC Technology To Participate In Cowen Technology Conference At 9:40 AM ET

Macy's To Hire More Than 41,000 Seasonal Colleagues

Ladders Sold With Bunk Bed And Hutch Sets Recalled

Lyft To Offer Rides For Indeed's Ready To Work Program

Pool And Spa Drain Covers Sold At Amazon Recalled

Target Unveils Holiday Offers; To Hire Up To 100K Seasonal Staff

GM Closes Reservations For Electric Hummer Pickup, SUV

Melissa's Dutch Red Potatoes With Dijon Mustard Sauce Recalled

Target Unveils Holiday Offers; To Hire Up To 100K Seasonal Staff

FDA Imposes Partial Hold On DBV Technologies' Phase III VITESSE Study

Ionis: AstraZeneca Decides Not To Advance ION449 Into Phase 3 Based On Pre-specified Criteria

Lyft To Offer Rides For Indeed's Ready To Work Program

GSK To Receive Licence From Spero To Develop, Commercialise Tebipenem Pivoxil HBr

Merck Animal Health To Buy Vence; Financial Terms Not Disclosed

Bausch Health, Glenmark Specialty Say Health Canada Approves RYALTRIS

AstraZeneca Announces Approval For Ultomiris By The European Commission

GSK : FDA Panel To Review Zejula Data From Phase III Trial In Recurrent Ovarian Cancer

U.S. District Court Rules In Favor Of Merck In Patent Infringement Suit Against Viatris

Veracyte: Data Suggests Cancer Risk Classification Using Clinical Factors Alone May Be Suboptimal

Avenue Therapeutics Sinks 25%; Shares Start Trading After Reverse Stock Split

Columbia Sportswear Backs FY22 Outlook; Stock Up In Pre-market

CVS Group FY22 Earnings Climb

Glencore To Acquire Newmont's Shareholding In MARA Project

Loop Media Offers 2.5 Mln Shares At $5/shr In IPO

Innocoll To Make $2 Mln Payment To DURECT On First Commercial Sale Of POSIMIR

GM Investment Arm Makes Strategic Investment In Lithion's Series A Financing Round

TreeHouse Foods Recalls Italian Dressing Due To Undeclared Allergens

Babcock Says Trading Continues To Be In Line With Board's FY Expectations

Frasers Now Intends To Seek To Buy Addl MySale Shares By Means Of Market Or Other Purchases

Ionis: AstraZeneca Decides Not To Advance ION449 Into Phase 3 Based On Pre-specified Criteria

US Air Force Selects Raytheon, Northrop Grumman To Develop Hypersonic Air-breathing Missile

Ascent Solar CEO Victor Lee Resigns